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Summary of findings {#CD009964-sec1-0001}
===================

Summary of findings for the main comparisonPre‐referral rectal artesunate compared to placebo for severe malaria**Pre‐referral rectal artesunate compared to placebo for preventing deaths from severe malariaPatient or population:** Children and adults with severe malaria **Settings:** Rural settings in Africa and Asia **Intervention:** Rectal artesunate and referral for further care **Comparison:** Placebo and referral for further care**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboRectal ArtesunateAll cause mortalityChildren aged 6 to 72 monthsRR 0.74** (0.59 to 0.93)8050 (1 study)⊕⊕⊕⊝ **moderate**^1,2,3,4^**41 per 100030 per 1000** (24 to 38)**Older children and adultsRR 2.21** (1.18 to 4.15)4018 (1 study)⊕⊕⊝⊝ **low**^1,5,6^**7 per 100015 per 1000** (8 to 29)**NeurodisabilityAll age groupsRR 0.68** (0.35 to 1.30)17,280 (1 study)⊕⊕⊝⊝ **low**^1,7^**3 per 10002 per 1000** (1 to 4)\*The **assumed risk** is the control group risk from the single included study. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the control group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratioGRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Background {#CD009964-sec1-0002}
==========

Description of the condition {#CD009964-sec2-0001}
----------------------------

Malaria remains an important global health challenge. In 2009 approximately 225 million clinical cases and 781,000 malaria‐related deaths occurred worldwide ([@CD009964-bbs2-0032]). The greatest burden of disease occurs in sub‐Saharan Africa where the highest risk is in children below the age of five years ([@CD009964-bbs2-0032]). The dominant parasite species *Plasmodium falciparum* accounts for over 95% of cases.

Severe or complicated malaria is characterized by signs of vital organ dysfunction, and prompt and effective drug treatment is required to prevent severe neurological deficit and death ([@CD009964-bbs2-0033]). Patients are often unable to take drugs by mouth because of repeated vomiting or a reduced level of consciousness, and parenteral treatment with either intravenous (IV) or intramuscular (IM) injections is preferred.

Description of the intervention {#CD009964-sec2-0002}
-------------------------------

Artesunate and artemether are antimalarial compounds derived from the herb *Artemisia annua*. Once administered these artemisinin‐derivatives are rapidly converted to the active metabolite dihydroartemisinin, which has been shown to rapidly clear malaria parasites from the peripheral blood ([@CD009964-bbs2-0012]). Artemisinin‐derivatives now form the backbone of the global malaria treatment strategy where they are used orally in artemisinin‐based combinations for uncomplicated malaria, or as injections for severe malaria ([@CD009964-bbs2-0033]).

Artesunate is the recommended first line treatment for severe malaria worldwide ([@CD009964-bbs2-0033]), and when given by intravenous or intramuscular injection has been shown to reduce deaths in both children and adults compared to the older alternative quinine ([@CD009964-bbs2-0010]; [@CD009964-bbs2-0011]). This effect has been consistent across all published randomized trials, and the most recent Cochrane review of artesunate versus quinine concluded that further studies comparing these two drugs parenterally are probably unnecessary ([@CD009964-bbs2-0027]).

In hospital‐based studies artesunate also appears to be reliably absorbed and effective when administered rectally. A systematic review ([@CD009964-bbs2-0021]) identified two studies directly comparing rectal artesunate with parenteral alternatives ([@CD009964-bbs2-0003]; [@CD009964-bbs2-0005]). These two studies were conducted in hospital settings, enrolled a total of 268 participants, and both reported a reduction in parasitaemia as the primary outcome. Neither were powered to look at mortality and only one patient died (after rectal treatment). Rectal artesunate was associated with superior reductions in parasitaemia at 12 and 24 hours compared to parenteral quinine ([@CD009964-bbs2-0003]) and intramuscular artemether ([@CD009964-bbs2-0005]). The review found no studies directly comparing rectal artesunate with parenteral artesunate.

A more recent review of pharmacokinetic data concluded that rectal artesunate had similar characteristics to oral administration but with a slightly shorter time to maximum plasma concentration (T~max~) ([@CD009964-bbs2-0024]). Rectal artesunate has the advantage of not having a first pass effect through the liver so bioavailability after administration is high ([@CD009964-bbs2-0024]). The rate of absorption in children is modified by the body temperature, with higher absorption positively correlated with rising body temperature ([@CD009964-bbs2-0020]). The volume of distribution is also influenced by body weight which in this context is a proxy for age ([@CD009964-bbs2-0020]; [@CD009964-bbs2-0028]).

How the intervention might work {#CD009964-sec2-0003}
-------------------------------

The risk of death from severe malaria is greatest within the first 24 hours of onset of illness ([@CD009964-bbs2-0023]). Treatment should therefore start as soon as possible in such patients, preferably before the referral process is completed. Ideally the drug should be given intravenously although current recommendations allow for intramuscular or rectal administration where this is not possible or available ([@CD009964-bbs2-0033]).

In most malaria endemic countries injectable formulations of artesunate and quinine and the necessary skill to give them are mainly concentrated in large healthcare facilities. The transit time to these facilities is often prolonged due to long distances and a lack of adequate transport. The resulting delays in accessing treatment could account for the high mortality associated with the disease ([@CD009964-bbs2-0023]). Indeed, results of verbal autopsy studies have demonstrated that the majority of patients with severe malaria never reached the hospital ([@CD009964-bbs2-0019]; [@CD009964-bbs2-0018]; [@CD009964-bbs2-0025]). Addressing this situation requires improvements in the initial emergency response package for identifying and treating cases of suspected severe malaria. Specifically, this would involve the use of effective drugs in formulations that can be easily administered by healthcare staff at the point of first contact, taking into account the level of skill available at such points. In this context artesunate suppositories offer a distinct potential advantage as a means of initiating treatment of severe malaria as they are easy to administer by individuals with minimal training ([@CD009964-bbs2-0029]).

Why it is important to do this review {#CD009964-sec2-0004}
-------------------------------------

The exact role of rectal artesunate in the management of malaria has remained the subject of discussion. While rectal artesunate provides a pragmatic solution for early treatment, its effects on mortality and morbidity are less clear. Furthermore, the rectal route of treatment may not be universally acceptable ([@CD009964-bbs2-0017]). Studies on the effects of rectal artesunate have mainly been conducted in hospitals ([@CD009964-bbs2-0008]; [@CD009964-bbs2-0003]) and are difficult to generalize to rural settings where a pre‐referral intervention is needed. A trial by Gomes and colleagues ([@CD009964-bbs2-0001]) evaluated the effects of a single dose rectal artesunate administered before referral on death and permanent disability and the trial was designed to address some of these questions ([@CD009964-bbs2-0014]). This trial\'s findings were used to inform recommendations ([@CD009964-bbs2-0033]). However, the results of this trial and the subsequent recommendation of rectal artesunate as pre‐referral treatment in severe malaria has been the subject of criticism. Notably, Hirji and Premji reported limitations in the design, implementation, analysis and interpretation of the trial data ([@CD009964-bbs2-0016]); while others questioned the ethics of using a placebo control group in patients considered to be critically ill ([@CD009964-bbs2-0009]).

These concerns indicated a real interest in this field and make this review timely. Given the importance of early intervention for the outcomes of severe malaria it is vital that we have a concise summary of the available evidence regarding the use of rectal artesunate at an important early stage in the management of severe malaria.

Objectives {#CD009964-sec1-0003}
==========

To evaluate the effects of pre‐referral treatment with rectal artesunate on mortality and morbidity in people with severe malaria.

Methods {#CD009964-sec1-0004}
=======

Criteria for considering studies for this review {#CD009964-sec2-0005}
------------------------------------------------

### Types of studies {#CD009964-sec3-0001}

Individual and cluster‐randomized controlled trials.

### Types of participants {#CD009964-sec3-0002}

Children and adults with any of the features of severe malaria as defined by the World Health Organization ([@CD009964-bbs2-0031]). We also considered trials where additional criteria such as inability to swallow oral drugs or need for hospitalization was used to define entry into the study.

### Types of interventions {#CD009964-sec3-0003}

Comparison 1: Artesunate given rectally before referral to a healthcare facility versus placebo.

Comparison 2: Artesunate given rectally before referral to a healthcare facility versus intramuscular or intravenous injections of an antimalarial drug.

### Types of outcome measures {#CD009964-sec3-0004}

#### Primary outcomes {#CD009964-sec4-0001}

All cause mortality.

#### Secondary outcomes {#CD009964-sec4-0002}

Neurodisability defined as any neurological deficit persisting beyond the acute phase of illness.Proportion of patients with severe malaria reaching a secondary healthcare facility.Proportion of patients with parasitaemia on admission in the secondary healthcare facility.Average parasite count per group on admission in the secondary healthcare facility.Time to presentation at healthcare facility.

Search methods for identification of studies {#CD009964-sec2-0006}
--------------------------------------------

We searched for all relevant trials regardless of language or publication status (published, unpublished, in press and in progress).

### Electronic searches {#CD009964-sec3-0005}

The search specialist at the editorial base searched the following databases up to May 2014 using search terms detailed in [Appendix 1](#CD009964-sec2-0016){ref-type="app"}: Cochrane Central Register of Controlled Trials (CENTRAL) published in The Cochrane Library; MEDLINE; EMBASE and LILACS. We also searched the WHO clinical trial registry platform and the metaRegister of Controlled Trials (mRCT) for ongoing trials.

### Searching other resources {#CD009964-sec3-0006}

We checked the reference lists of included studies identified from the above mentioned methods.

Data collection and analysis {#CD009964-sec2-0007}
----------------------------

### Selection of studies {#CD009964-sec3-0007}

The review authors (JO and ME) independently screened titles and abstracts of the search results for potentially eligible trials. Following agreement on what trials need further review we retrieved the full text of these articles and applied the eligibility criteria as above mentioned. Trials that did not meet the criteria were excluded and the reasons for exclusion were summarized in the \"[Characteristics of excluded studies](#CD009964-sec2-0020){ref-type="sec"}\" table.

### Data extraction and management {#CD009964-sec3-0008}

JO and ME extracted data from the included trials and JO entered these in the table of [Characteristics of included studies](#CD009964-sec2-0019){ref-type="sec"}. JO resolved differences in the data by discussion with ME.

We extracted the following information:

Start and end dates, location and details of the trial design.Background of the trial sites: malaria endemicity; available healthcare services; distance to healthcare facilities when stated.Eligibility (inclusion and exclusion) criteria of the participants, including the sample size and ages.Details about the interventions: type and dose of suppositories used.The type and cadre of staff administering the treatment.The method used for the diagnosis of severe malaria.The methods used for ruling out diseases other than malaria.For each outcome we noted the number of participants analyzed for each group as well as attrition. For dichotomous outcomes we also recorded the number of participants that experienced the event. For count data we planned to extract the number of events per group and the total person time at risk in each group (where feasible).

### Assessment of risk of bias in included studies {#CD009964-sec3-0009}

JO and ME independently assessed the risk of bias in the included trial using the Cochrane Collaboration's risk of bias tool ([@CD009964-bbs2-0015]). We included the following assessment categories: sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and \"other bias\" (such as clustering). We assigned judgements as either \"yes\" (low risk of bias), \"no\" (high risk of bias) or \"unclear\". We resolved differences through discussion and reaching consensus, and summarized the results of the assessment in [Figure 1](#CD009964-fig-0001){ref-type="fig"}.Figure 1Risk of bias summary: review authors\' judgements about each risk of bias item for the included trial.

### Measures of treatment effect {#CD009964-sec3-0010}

We used risk ratios (RR) to measure treatment effects for dichotomous outcomes (death from all causes; presence of neurodisability; percentage reaching hospital; percentage with parasitaemia). We presented count data as rate ratios because we could not analyze them as continuous data (average parasite count per group as these were presented as categories). All measures were presented with 95% confidence intervals (CIs). We performed subgroup analysis for dichotomous outcomes by age and region (Africa versus Asia).

### Unit of analysis issues {#CD009964-sec3-0011}

The unit of analysis was individuals and we analyzed the data accordingly using methods described previously ([@CD009964-bbs2-0015]).

### Dealing with missing data {#CD009964-sec3-0012}

We performed intention‐to‐treat analyses by including all outcome data available in the article, irrespective of whether the participants completed the trial or not.

### Assessment of heterogeneity {#CD009964-sec3-0013}

We assessed for statistical heterogeneity between subgroups by visually inspecting the forest plots for overlapping confidence intervals, applying the Chi^2^ test (where a P value \< 0.10 is considered statistically significant), and by using the I^2^ statistic (with values \> 40% representing moderate heterogeneity, \> 60% substantial heterogeneity, and \> 80% considerable heterogeneity).

### Assessment of reporting biases {#CD009964-sec3-0014}

We assessed if trial outcomes were reported for all randomized participants by comparing the proportions of those with outcomes against the number enrolled in each trial arm. Where this was not the case, we checked to see if there was an explanation for the difference.

### Data synthesis {#CD009964-sec3-0015}

JO analyzed the data using ([@CD009964-bbs2-0026]) software and applied a fixed‐effect model. Because we only included one trial we could not do meta‐analyses however, effect sizes were calculated for all outcomes. We assessed the quality of evidence for the most important outcomes using the GRADE approach, and presented the judgements in a Summary of Findings table.

### Subgroup analysis and investigation of heterogeneity {#CD009964-sec3-0016}

Where statistical heterogeneity was observed we investigated the influence of trial characteristics with subgroup analysis by age (6 to 72 months versus \> 72 months), trial region (Africa or Asia) and whether the participants were included in the trial analysis or not.

Results {#CD009964-sec1-0005}
=======

Description of studies {#CD009964-sec2-0008}
----------------------

### Results of the search {#CD009964-sec3-0017}

The search identified 38 potentially relevant publications of which only one was eligible ([@CD009964-bbs2-0001]). We excluded thirty articles after reviewing the titles and abstracts, and a further seven publications were excluded with reasons after we reviewed the full text ([Figure 2](#CD009964-fig-0002){ref-type="fig"}). We did not find any trial that evaluated our second comparison.Figure 2Search results and article selection.

### Included studies {#CD009964-sec3-0018}

The trial by Gomes and colleagues ([@CD009964-bbs2-0001]) was a community‐based individually randomized placebo‐controlled trial involving 291 villages in three countries with different levels of malaria transmission: Bangladesh (149 villages) with a low unstable transmission and two African countries, Ghana and Tanzania (142 villages), with high transmission. A total of 17,826 children and adults with suspected severe malaria were randomized to receive either a single artesunate suppository (n = 8954) or placebo (n = 8872). The trial report focused on 12,068 participants (6072 artesunate; 5996 placebo); 5758 (32.3%) participants were excluded from the primary analysis because they had either received an antimalarial injection around the time of randomization (n = 1110) or were retrospectively observed to have a negative blood smear at the time of randomization (n = 4648).

Trial participants were categorized as children aged 6 to 72 months (67%, n = 8050), or older children and adults (aged over 72 months). Only children aged between 6 and 72 months were recruited at the African sites and made up 75% of the total in this group ([Table 3](#CD009964-tbl-0003){ref-type="table"}). Children aged 6 to 72 months received 100 mg artesunate while the rest received 400 mg artesunate rectally and all were subsequently referred to a healthcare facility (clinic or hospital). Mortality was assessed at the healthcare facility and during home visits carried out 7 to 30 (median 14) days after randomization ([Characteristics of included studies](#CD009964-sec2-0019){ref-type="sec"}).Table 1Differences Between African and Asian sites**FeatureAfricaAsia**Number analyzed in trial report60406028Participants aged 6 to 72 months60402010Participants above 72 months04018Number without a blood slide10208Death within 6 hours after enrolment8127Not reached a hospital within 6 hours after randomization2686399

### Excluded studies {#CD009964-sec3-0019}

Of the seven excluded articles four were trials that gave artesunate to participants in hospital ([@CD009964-bbs2-0003]; [@CD009964-bbs2-0002]; [@CD009964-bbs2-0005]; [@CD009964-bbs2-0004]), one was a secondary publication based on [@CD009964-bbs2-0003], one was an opinion paper addressing ethical issues with using placebo as control group in the included trial ([@CD009964-bbs2-0006]) and one trial excluded participants with severe malaria ([@CD009964-bbs2-0007]).

Risk of bias in included studies {#CD009964-sec2-0009}
--------------------------------

The risk of bias assessment relates to the one included trial ([@CD009964-bbs2-0001]).

### Allocation {#CD009964-sec3-0020}

Participants were allocated to either the intervention or control groups by making use of consecutively numbered treatment boxes. A computer was used to generate the allocation sequence by means of block‐randomization.

### Blinding {#CD009964-sec3-0021}

All trial staff were blinded to the treatment allocation until the endpoints were finalized.

### Incomplete outcome data {#CD009964-sec3-0022}

The trial authors described their analysis to be an \"intention to treat\" analysis. However, results were presented for 12,068 (68%) participants and 5758 (32%) randomized participants were excluded from the analysis because either the blood slide collected on enrolment and read at the referral hospital was negative (4648 participants) or they had received an injection with an antimalarial shortly before randomization (1110 participants).

### Selective reporting {#CD009964-sec3-0023}

The trial authors did not report all pre‐specified outcomes as per the protocol in the trial registry however, there was no evidence from the data that they were excluded. The risk of selective outcome reporting in the published report of the trial was low.

### Other potential sources of bias {#CD009964-sec3-0024}

Most of the children aged between 6 and 72 months were recruited from sites in Africa while all older children and adult participants were from the sites in Bangladesh. Mortality and presentation at a healthcare facility were quite different between the African and Asian sites and this could have been due to differences in the distance to, or the quality of, care at these referral facilities ([Table 3](#CD009964-tbl-0003){ref-type="table"}). One of the African sites with 1020 (16.9%) trial participants did not collect a blood slide at randomization but these were included in the trial analysis. Only 8 (0.1%) participants recruited in Bangladesh did not have a blood slide at randomization.

Effects of interventions {#CD009964-sec2-0010}
------------------------

See: [Table 1](#CD009964-tbl-0001){ref-type="table"}

### Comparison: Artesunate given rectally before referral to a health facility versus placebo {#CD009964-sec3-0025}

#### All cause mortality {#CD009964-sec4-0003}

Overall, there was no evidence of a difference in mortality with rectal artesunate compared to placebo for all participants analyzed in the trial (all ages across African and Asian sites) (RR 0.86; 95% CI 0.69 to 1.06; 12,068 participants; [Analysis 1.1](#CD009964-fig-00101){ref-type="fig"}). There was also no evidence of a difference in the intention‐to‐treat analysis of all randomized participants which included those excluded from the trial\'s primary analysis due to negative blood smears or receiving an antimalarial injection before randomization (RR 0.89; 95% CI 0.75 to 1.05; 17,826 participants; [Analysis 1.1](#CD009964-fig-00101){ref-type="fig"}).

In young children (aged 6 to 72 months; African and Asian sites) rectal artesunate was associated with a reduced risk of death compared to placebo (RR 0.74; 95% CI 0.59 to 0.93; 8050 participants; [Analysis 1.2](#CD009964-fig-00102){ref-type="fig"}), although the magnitude of this effect varied between the African (RR 0.81; 95% CI 0.63 to 1.04; 6040 participants) and the Asian sites (RR 0.45; 95% CI 0.24 to 0.85; 2010 participants).

In older children and adults (Asian sites only) rectal artesunate was associated with a more than two‐fold increase in the risk of death compared to placebo (RR 2.21; 95% CI 1.18 to 4.15; P = 0.01; 4018 participants; [Analysis 1.3](#CD009964-fig-00103){ref-type="fig"}).

#### Neurodisability {#CD009964-sec4-0004}

Neurodisability as an outcome in the trial was rare with only 15 participants diagnosed with a disability (2/5918 in the artesunate group versus 13/5819 in the placebo group). This difference reached statistical significance (RR 0.15; 95% CI 0.03 to 0.67; 11,737 participants; [Analysis 1.4](#CD009964-fig-00104){ref-type="fig"}), but when we re‐analyzed including the 5543 randomized participants excluded from the trial\'s primary analysis the result was no longer statistically significant (RR 0.68; 95% CI 0.35 to 1.30; 17,280 participants; [Analysis 1.4](#CD009964-fig-00104){ref-type="fig"}).

#### Severe malaria on admission {#CD009964-sec4-0005}

There was no difference in the proportion of participants with severe malaria (coma, repeated convulsions, or prostration) on arrival at a healthcare facility between those given rectal artesunate or placebo (RR 1.01; 95% CI 0.90 to 1.14; 12,068 participants; [Analysis 1.5](#CD009964-fig-00105){ref-type="fig"}). This finding was consistent for all age categories and trial regions.

#### Parasitaemia on admission {#CD009964-sec4-0006}

There was no difference between the rectal artesunate or placebo groups in the proportion of participants with parasitaemia on admission (RR 1.00; 95% CI 0.98 to 1.02; 17,826 participants; [Analysis 1.6](#CD009964-fig-00106){ref-type="fig"}).

#### Proportion reaching hospital within six hours {#CD009964-sec4-0007}

There was also no difference between the two groups in the proportion of participants who reached a healthcare facility within six hours (RR 0.99, 95% CI 0.98 to 1.01; 12,068 participants; [Analysis 1.7](#CD009964-fig-00107){ref-type="fig"}). However, the proportion that had not reached a hospital within this period was very different between regions where almost half of all participants in Africa failed to reach a facility within six hours (2686/6040; 44.5%) compared to less than 10% in Asia (399/6028; 6.6%) ([Table 3](#CD009964-tbl-0003){ref-type="table"}).

Discussion {#CD009964-sec1-0006}
==========

Summary of main results {#CD009964-sec2-0011}
-----------------------

Rectal artesunate as a pre‐referral intervention showed diverging effects on all cause mortality in different age groups with severe or complicated malaria. In young children rectal artesunate probably reduces the risk of death by 26% (moderate quality evidence) while in older children and adults rectal artesunate may increase risk of death (low quality evidence).

The risk of neurodisability was low with both rectal artesunate and placebo, without a statistically significant difference between groups (low quality evidence).

Overall completeness and applicability of evidence {#CD009964-sec2-0012}
--------------------------------------------------

The single included trial was conducted to evaluate the use of rectal artesunate in a very specific scenario; rural communities without access to injectable antimalarials, and as such includes a placebo control group rather than the prior standard of care; parenteral artesunate or quinine. The findings of this review are therefore only directly applicable to similar settings. Indeed, despite extensive searching we found no trials comparing pre‐referral rectal artesunate with either intramuscular quinine, artesunate or artemether.

The trial included a mix of African and Asian trial sites across a range of malaria transmission settings. However, there are several differences between the study sites which complicate interpretation of the results ([Table 3](#CD009964-tbl-0003){ref-type="table"}). Older children and adults were only enrolled in Asia, making it impossible to determine if the harm detected in older children and adults is specific to Asia or consistent across regions, and trial participants in Bangladesh were able to access definitive care much quicker than those in Africa, which may explain the lower mortality seen at the Asian sites.

The finding that rectal artesunate reduced the risk of death in young children but increased the risk of death in older children and adults is both unexpected and difficult to explain. There is some evidence that the profile of severe or complicated malaria differs between children and adults ([@CD009964-bbs2-0030]), but a review of artemisinin‐derivatives in severe malaria has shown consistent benefits in children and adults with only variation in the magnitude of the benefit ([@CD009964-bbs2-0027]). We attempted to understand this finding but without other trials to confirm or refute the findings we can not provide a plausible explanation. The small number of deaths recorded in older children and adults in Asia raises the possibility that this is a chance finding, but other explanatory factors may be the higher dose administered, differences in the care received, or a true differential effect of age in the host response to severe malaria. Undoubtedly, this finding has implications for policy recommendations regarding rectal artesunate in older children and adults.

The primary analysis in the trial excluded a large proportion of the randomized participants. This decision was made before unblinding, and we did not detect major differences in results when these participants were added back into the analysis. The rationale for the time and age cut‐offs used in the analysis are less clear.

Despite the limitations, and questions arising from this single trial, it is unlikely that a trial of this size will ever be repeated due to the challenges of recruiting an adequate sample size, and the decline in malaria transmission globally. There is also the ethical question of the use of a placebo in a potentially life threatening situation with little option for rapid intervention if the condition deteriorates. Consequently, the observed harmful effect in children older than 72 months and adults may remain unexplained.

Quality of the evidence {#CD009964-sec2-0013}
-----------------------

We assessed the quality of the evidence using the GRADE approach, and our judgements are presented in [Table 1](#CD009964-tbl-0001){ref-type="table"}.

We consider the data available from the trial sites in Asia to provide only *low quality evidence* of a benefit in young children and a harm in older children and adults. The main limitation was the low number of events (deaths) in both age categories at this site, which means the trial was not powered to confidently detect these effects. This limitation raises the possibility that these are both chance findings. We have therefore downgraded for serious imprecision, and for serious inconsistency due to the opposite effects in the two age groups; a finding which is both unexpected and unexplained.

However, we considered the data in young children from Africa and Asia to provide *moderate quality evidence* of a reduction in death with rectal artesunate in this age group. This means that we have moderate confidence that rectal artesunate is beneficial in this age group. We downgraded the evidence from high due to the inconsistency in effect between the two regions (with a smaller effect seen in Africa). We also considered downgrading for imprecision because the result in Africa did not reach statistical significance without the addition of the Asian data. However, after discussion we did not consider this issue sufficient to further downgrade.

We also note that the absolute benefit of pre‐referral rectal artesunate in young children is relatively small, saving just 10 more lives per 1000 people treated than referral alone (with placebo). This is of smaller magnitude than the additional benefits of parenteral artesunate versus parenteral quinine (26 additional lives saved per 1000 people treated, [@CD009964-bbs2-0027]).

Potential biases in the review process {#CD009964-sec2-0014}
--------------------------------------

We did not identify any specific bias in our review process.

Agreements and disagreements with other studies or reviews {#CD009964-sec2-0015}
----------------------------------------------------------

We found no other reviews of pre‐referral rectal artesunate. We did however find three reviews of trials evaluating the effect of rectal artemisinins compared to conventional treatments for severe malaria (parenteral artemisinins and quinine) in hospital‐based care settings ([@CD009964-bbs2-0013]; [@CD009964-bbs2-0021]; [@CD009964-bbs2-0034]). The most recent of these reviews ([@CD009964-bbs2-0013]) used individual patient data from three published and three unpublished studies to compare rectal and parenteral artemisinin‐derivatives. However, none of the studies in the review directly compared rectal with parenteral artesunate, or directly assessed pre‐referral treatment. The review authors concluded that rectal artesunate was effective at reducing parasitaemia during the first 24 hours after treatment and could be an option in remote rural settings ([@CD009964-bbs2-0013]) and this formed the background for the included trial ([@CD009964-bbs2-0001]).

The authors of the single included trial in our review concluded that \"if patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate suppository at the time of referral substantially reduces the risk of death or permanent disability\". We would suggest an amendment to limit the conclusion to children aged between 6 and 72 months.

Authors\' conclusions {#CD009964-sec1-0007}
=====================

In rural settings without access to injectable antimalarials, rectal artesunate probably reduces mortality in young children (6 to 72 months old) being transported to hospital for further care. However, the unexpected finding of possible higher mortality in older children and adults should be taken into account when forming national and local policies about pre‐referral treatment.The concerns about increased mortality with pre‐referral rectal artesunate in older children and adults will not be resolved without further trials. However, it is unlikely that these trials will be done, due to the large sample size required and the ethical issues related to the use of a placebo group.

The academic editor for this review was Professor Paul Garner.

We thank the Cochrane Infectious Diseases Group for their support of this project.The editorial base for the Cochrane Infectious Diseases Group is funded by the UK Department for International Development for the benefit of developing countries.
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a = Cochrane Infectious Diseases Group Specialized Register

b = Search terms for retrieving trials, developed by The Cochrane Collaboration ([@CD009964-bbs2-0022]), was also used in combination of the search terms reported in the above table to search these databases.

Comparison 1Pre‐referral artesunate vs PlaceboOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All cause mortality (all enrolled)](#CD009964-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 1 All cause mortality (all enrolled).117826Risk Ratio (M‐H, Fixed, 95% CI)0.89 \[0.75, 1.05\]1.1 Blood smear negative14648Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.64, 1.21\]1.2 Antimalarial injection just before randomization11110Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.68, 1.70\]1.3 Analyzed in trial report112068Risk Ratio (M‐H, Fixed, 95% CI)0.86 \[0.69, 1.06\][2 All cause mortality (young children)](#CD009964-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 2 All cause mortality (young children).18050Risk Ratio (M‐H, Fixed, 95% CI)0.74 \[0.59, 0.93\]2.1 Africa16040Risk Ratio (M‐H, Fixed, 95% CI)0.81 \[0.63, 1.04\]2.2 Asia12010Risk Ratio (M‐H, Fixed, 95% CI)0.45 \[0.24, 0.85\][3 All cause mortality (older children/adults)](#CD009964-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 3 All cause mortality (older children/adults).14018Risk Ratio (M‐H, Fixed, 95% CI)2.21 \[1.18, 4.15\][4 Neurodisability (all participants)](#CD009964-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 4 Neurodisability (all participants).117280Risk Ratio (M‐H, Fixed, 95% CI)0.68 \[0.35, 1.30\]4.1 Excluded in trial analysis15543Risk Ratio (M‐H, Fixed, 95% CI)1.44 \[0.62, 3.36\]4.2 Analyzed in trial report111737Risk Ratio (M‐H, Fixed, 95% CI)0.15 \[0.03, 0.67\][5 Severe malaria on admission (coma, repeated convulsions or prostration)](#CD009964-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 5 Severe malaria on admission (coma, repeated convulsions or prostration).112068Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.90, 1.14\]5.1 Asia (6 to 72 months)12010Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.74, 1.30\]5.2 Asia (older child/adult)14018Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.81, 1.33\]5.3 Africa (6 to 72 months)16040Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.87, 1.19\][6 Proportion with parasitaemia on admission](#CD009964-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 6 Proportion with parasitaemia on admission.117826Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.98, 1.02\][7 Proportion reaching a hospital within 6 hours](#CD009964-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Pre‐referral artesunate vs Placebo, Outcome 7 Proportion reaching a hospital within 6 hours.112068Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.98, 1.01\]7.1 Africa16040Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.95, 1.04\]7.2 Asia16028Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.98, 1.01\]

**DateEventDescription**20 August 2014AmendedCorrected typographical error in the abstract

We changed the primary outcome from \"deaths from severe malaria\" to \"all cause mortality\". The Cochrane Infectious Disease Group policy is that in severe malaria the main outcome should be all cause mortality because \"deaths caused by malaria\" is more subject to bias. The error was not detected previously by the co‐ordinating editor and was also not detected by referees.

Characteristics of included studies \[ordered by study ID\] {#CD009964-sec2-0019}
===========================================================

[@CD009964-bbs2-0001]MethodsCommunity‐based individually randomized placebo‐controlled\
Length of follow‐up: 7 to 30 days\
Mortality was assessed at the clinic and during home visits carried out 7 to 30 days after randomization (median 14 days).Participants17,826 participants recruited from 291 rural villages in Africa (Ghana, Tanzania; 142) and Asia (Bangladesh; 149)\
Intervention group (rectal artesunate)=8954, control group (placebo)= 8872\
Number analyzed and reported in trial result: 12,068 (intervention= 6072, control= 5996)\
46% of participants (n = 5504) were female and information on gender was missing for two participants; (one in each group).\
Age range: 6 to 72 months (African and Asian trial sites); participants \> 72 months recruited only from sites in Bangladesh (Asia)\
Inclusion criteria: suspected malaria determined by trained resident recruiters, and participants unable to swallow\
Exclusion criteria at screening: not stated\
Reported baseline characteristics did not show any differences between the trial groupsInterventionsArtesunate (100 mg and 400 mg for the younger children and older children and adults respectively) versus placebo.\
Participant received either artesunate or placebo suppository of identical appearance, sealed in a waterproof sachet. After insertion, the buttocks held together for about 10 min to prevent expulsion. Participants were considered included in trial on successful insertion even if the suppository was later expelledOutcomesMortality at 7 to 30 days after randomization\
Permanent disability 7 to 30 days after randomization\
Eight participants (0·07%), all in the placebo group, were lost to follow‐ up.NotesDifferent malaria transmission characteristics: high (Ghana, Tanzania); low and unstable (Bangladesh)\
The trial was conducted between August 2000 and July 2006.\
Treatment administered by resident village recruiters with little previous medical knowledge and no research experience; they got monitored by field supervisors\
Data for participants \> 72 months old were from one site\
Access to and quality of available care at referral hospital was notably different between African and Asian sites\
Determination of alternative diagnosis was ruled out by expert opinion\
Trial Registration: [http://www.controlled‐trials.com/ISRCTN83979018](http://www.controlled‐trials.com/ISRCTN83979018); [http://www.controlled‐trials.com/ISRCTN46343627](http://www.controlled‐trials.com/ISRCTN46343627)**;**[http://www.controlled‐trials.com/ISRCTN76987662](http://www.controlled‐trials.com/ISRCTN76987662)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskused computer generated block‐balanced boxes of 4 or 8 random allocationsAllocation concealment (selection bias)Low riskConsecutively numbered treatment boxesBlinding of participants and personnel (performance bias) All outcomesLow riskAll trial staff were blinded until after the endpoints were finalizedBlinding of outcome assessment (detection bias) All outcomesLow riskAlthough some participants initially randomized were excluded from analysis, this was done before unblinding.Incomplete outcome data (attrition bias) All outcomesUnclear risk5758 (32%) of participants were excluded from the analysis after randomization. This was documented as a pre‐unblinding decision in trial publication.Selective reporting (reporting bias)Low riskThe protocol is available and the trial authors addressed all of the important and pre‐specified outcomesOther biasUnclear riskDifference in age distribution of recruited participants and in proportion of participants without blood slide at recruitment between the African and Asian regions,

Characteristics of excluded studies \[ordered by study ID\] {#CD009964-sec2-0020}
===========================================================

StudyReason for exclusion[@CD009964-bbs2-0002]Rectal artesunate given in hospital[@CD009964-bbs2-0003]Rectal artesunate given in hospital and patients with moderate malaria included[@CD009964-bbs2-0004]Rectal artesunate given in hospital[@CD009964-bbs2-0005]Rectal artesunate given in hospital[@CD009964-bbs2-0006]Discussion of [@CD009964-bbs2-0001][@CD009964-bbs2-0007]Excluded patients with severe malaria

JO wrote the background to the protocol and the objectives. ME wrote the methods section and search terms. ME reviewed the draft manuscript. Both authors reviewed the final draft before submission.

For the review, JO analyzed the data and wrote the draft of the review and ME reviewed the draft of the review.

We have no conflicts of interest to declare.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^ No serious risk of bias: Allocation was concealed and trial participants and staff were blinded to treatment allocation. ^2^ Downgraded by 1 for serious inconsistency: In both Africa and Asia there was a trend towards benefit with rectal artesunate in this age group. However in Africa, where most of the deaths occurred, and where almost half of participants failed to reach secondary care within six hours, the magnitude of the effect was smaller and did not reach statistical significance (RR 0.81; 95% CI 0.63 to 1.04). ^3^ No serious indirectness: Children aged 6 to 72 months were recruited from community settings in Tanzania, Ghana and Bangladesh. ^4^ No serious imprecision: The overall result reached statistical significance and was adequately powered to detect this effect. ^5^ Downgraded by 1 for serious indirectness: Older children and adults were only recruited from community settings in Bangladesh. This result may not easily be generalized to elsewhere. ^6^ Downgraded by 1 for serious imprecision: There were very few deaths in this group, and the trial was underpowered to detect this effect. ^7^ Downgraded by 1 for serious imprecision: Too few events, wide confidence interval, single site.
